tiprankstipranks
Trending News
More News >
CASI Pharmaceuticals (CASI)
NASDAQ:CASI
US Market
Advertisement

CASI Pharmaceuticals (CASI) Drug Pipeline

Compare
470 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
Cid-103
Chronic Immune Thrombocytopenia
Phase I/II
Recruiting
A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia
Jun 04, 2025
Cid-103
Multiple Myeloma
Phase I
Completed
CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma
Feb 08, 2021
Enmd-2076
Advanced Adult Hepatocellular Carcinoma, Advanced Fibrolamellar Carcinoma
Phase II
Completed
A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
Sep 05, 2014

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does CASI Pharmaceuticals (CASI) have in its pipeline
      CASI is currently developing the following drugs: Cid-103, Cid-103, Enmd-2076. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis